Home > Journals > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Past Issues > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 October;158(5) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 October;158(5):151-7

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Share

 

CLINICAL CASES   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 1999 October;158(5):151-7

Copyright © 1999 EDIZIONI MINERVA MEDICA

language: English

Toxoplasmosis and cardiovascular disorders

Barbosa Vosgerau J. C.

Dermalogist, Centro Municipal de Especialidades, Secretary of Health from Ponta Grossa, Brasil


PDF


Chlamydia pneu­mon­i­ae has ­been ­claimed to ­have a cen­tral ­role in the pa­thoph­y­sio­lo­gy of ath­ero­scler­o­sis and cor­o­nary ar­tery dis­ease, and rox­ith­rom­y­cin, an im­por­tant ­role in pre­vent­ing ­death, ­acute myo­car­dial in­farc­tion and re­cur­rent an­gi­na pec­tor­is. Three pa­tients are re­port­ed ­with chron­ic tox­o­plas­mo­sis ­with mul­ti­ple com­plaints in dif­fer­ent com­bi­na­tions ­such as ex­an­thema mor­bil­i­form, fe­ver, ar­thral­gia/ bone ­pain, mul­ti­plex mono­neu­rop­a­thy, pto­sis, hy­po­ten­sion, ­heart fail­ure, tach­y­car­dia, an­gi­na pec­tor­is, hy­per­ten­sion re­cal­ci­trant to usu­al ­anti-hy­per­ten­sive ­drugs ­with ECG al­ter­a­tions ­such as ST chang­es and “T” ­wave dif­fuse chang­es, eo­sin­o­phil­ia, leu­ko­pe­nia, leu­ko­cy­to­sis. There was re­mis­sion of ­those symp­toms and of car­di­o­vas­cu­lar dis­or­ders ­with anti­tox­o­plas­mo­sis treat­ment, us­ing a trip­let ­drugs ­scheme, par­tic­u­lar­ly ­with rox­ith­rom­y­cin 900 mg/day dap­sone and py­ri­meth­a­mine. These car­di­o­vas­cu­lar dis­or­ders and oth­er com­plaints re­lapsed as the tox­o­plas­mo­sis med­i­cines ­were inter­rupt­ed. It is pos­tu­lat­ed ­that in­creased ­host IFN-γ lev­els trig­gered by Toxoplasma has a cen­tral ­role in tox­o­plas­mo­sis pa­thoph­y­sio­lo­gy and ­when as­so­ciat­ed ­with oth­er cy­to­kines ­such as TNF-α may in­duce ­heart fail­ure and sep­tic ­shock and ­with IFN-α, an­gi­na pec­tor­is and hy­per­ten­sion. So the clin­i­cal/la­bor­a­to­ry dis­or­ders re­port­ed ­above are ­part of the tox­o­plas­mo­sis re­ac­tion­al ­state. It ­seems ­that ath­ero­scler­o­sis, cor­o­nary ar­tery dis­ease and ­heart fail­ure may not be age-re­lat­ed car­di­o­vas­cu­lar de­gen­er­a­tive dis­or­ders, but re­spons­es to chron­ic cy­to­kines-re­lat­ed stim­u­la­tion, ­where IFN-γ trig­gered by intra­cel­lu­lar par­a­sites ­such as Toxoplasma has a cen­tral ­role in ­their pa­thoph­y­sio­lo­gy. Early di­ag­no­sis and treat­ment of chron­ic tox­o­plas­mo­sis us­ing a trip­let ­drug ­scheme ­with rox­yth­rom­y­cin, dap­sone and py­ri­meth­a­mine may pre­vent ­late and se­vere car­di­o­vas­cu­lar com­pli­ca­tions ­like ­death, un­stable an­gi­na pec­tor­is, myo­car­dial in­farc­tion and ­rebel hy­per­ten­sion.

top of page